Drug Trial Radar · NCT04047862
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
446
Actual
Start
Aug 15, 2019
Primary completion
Aug 7, 2024
Study completion Aug 7, 2024
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Aug 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as ociperlimab) in combination with tislelizumab in participants with advanced solid tumors in phase 1. Primary objective of Phase 1b was to assess overall response rate (ORR) determined by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1 for patients in each dose-expansion cohort.
Conditions
- Locally Advanced and Metastatic Solid Tumors
Interventions
OciperlimabDrug
Administered as an intravenous (IV) injection
TislelizumabDrug
Administered as an IV injection
PemetrexedDrug
Administered in accordance with local guidelines, prescribing information/summary of product
PaclitaxelDrug
Administered in accordance with local guidelines , prescribing information/summary of product
Nab paclitaxelDrug
Administered in accordance with local guidelines , prescribing information/summary of product
CarboplatinDrug
Administered in accordance with local guidelines , prescribing information/summary of product
CisplatinDrug
Administered in accordance with local guidelines , prescribing information/summary of product
EtoposideDrug
Administered in accordance with local guidelines , prescribing information/summary of product
5fluorouracilDrug
Administered in accordance with local guidelines , prescribing information/summary of product
OxaliplatinDrug
Administered in accordance with local guidelines , prescribing information/summary of product
CapecitabineDrug
Administered in accordance with local guidelines , prescribing information/summary of product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Up to 30 days after the last dose of study interventions (up to 35.7 months [Dose escalation cohorts] and up to 13.3 months [Dose verification cohorts])
- Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days (for Dose escalation cohorts) and up to 21 days (for Dose verification cohorts)
- Phase 1: Maximum Administered Dose (MAD) of Ociperlimab in Combination With TislelizumabTime frame: Up to 28 days (Dose escalation cohort)
- Phase 1: Recommended Phase 2 Dose (RP2D) of Ociperlimab in Combination With TislelizumabTime frame: up to 28 days (Dose escalation cohorts)
- Phase 1b: Overall Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1Time frame: Maximum time duration on study: up to 41.6 months (Cohorts 1 to 9) and up to 21.4 months (Cohort 10)
Locations
65 sites in 6 countries. Site status is shown where the registry gives one.
Mayo Clinic Phoenix
Phoenix, Arizona
Scri Florida Cancer Specialists South
Fort Myers, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida
Scri Florida Cancer Specialists North
St. Petersburg, Florida
University of Kansas Medical Center Research Institute
Kansas City, Kansas
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Providence Portland Medical Center
Portland, Oregon
Tennessee Oncology, Pllc Nashville
Nashville, Tennessee
Medical College of Wisconsin
Milwaukee, Wisconsin
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia
Chris Obrien Lifehouse
Camperdown, New South Wales, Australia
Pindara Private Hospital
Benowa, Queensland, Australia
Icon Cancer Foundation
South Brisbane, Queensland, Australia
Metro South Health, Cancer Trials Unit Division of Cancer Services Pah
Woolloongabba, Queensland, Australia
Ashford Cancer Centre Research Northeast
Windsor Gardens, South Australia, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Bendigo Health
Bendigo, Victoria, Australia
Monash Health
Clayton, Victoria, Australia
St Vincents Hospital
Fitzroy, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
St John of God Health Care
Subiaco, Western Australia, Australia
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Tongren Hospital, Cmu
Beijing, Beijing Municipality, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Beijing Luhe Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Jilin Cancer Hospital
Changchun, Jilin, China
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, Shaanxi, China
Jinan Central Hospital
Jinan, Shandong, China
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.